- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05434819
Essai d'efficacité de l'ablation chirurgicale de la FA (SAFE)
SAFE is an international multicentre RCT of concomitant surgical atrial fibrillation (AF) ablation in patients with paroxysmal or persistent AF undergoing cardiac surgery.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Atrial fibrillation (AF) affects more than 1% of the general population and is an important risk factor for stroke. AF prevalence increases with age, occurring in 10 to 15% of patients older than 80 years of age, which is important with the aging population. Of patients undergoing cardiac surgery, 10.8% have a history of AF. AF is believed to cause the left atrium to dilate and lose its transport function. AF significantly increases the risk of ischemic stroke of cardioembolic origin, but is also associated with heart failure and impairs quality of life. Although the causal relationship between the 2 clinical entities has not been fully elucidated, AF is believed to cause heart failure via several mechanisms.
Ablation of AF is the application of scars to the atrial tissue to disrupt faulty electrical signals that cause the arrhythmia. If surgical ablation of AF yields a benefit similar to catheter-based AF ablation, thousands of people undergoing cardiac surgery could benefit from this procedure each year. SAFE will be a landmark trial in cardiac surgery, definitely establishing surgical AF ablation's impact on cardiovascular outcomes. Cardiac surgery is the optimal setting to establish whether maintenance of sinus rhythm through AF ablation yields clinical benefit, and is a setting where sham-control is possible. This will not only provide evidence for the cardiac surgical patients but will bolster the evidence for ablation (catheter or stand-alone surgical) in other AF patients.
The intervention under investigation is concomitant surgical AF ablation which is compared to no surgical AF ablation. The primary outcome is hospital readmissions with heart failure during 4 years of follow-up. This study will enroll 2000 patients from 50 centres, globally. Patients will be followed at hospital discharge, 4 to 6 weeks after surgery, 6 months after surgery, and then at 6-month intervals until the final follow-up visit, for a median follow-up for 4 years.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Richard Whitlock
- Numéro de téléphone: 905-521-2100
- E-mail: Richard.Whitlock@phri.ca
Sauvegarde des contacts de l'étude
- Nom: SAFE Coordinators
- E-mail: SAFE@phri.ca
Lieux d'étude
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Recrutement
- Hamilton General Hospital
-
Contact:
- Richard Whitlock, MD PhD FRCSC
- Numéro de téléphone: 40306 905-527-4322
- E-mail: richard.whitlock@phri.ca
-
Chercheur principal:
- Richard Whitlock, MD MSc FRCSC
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ≥ 18 years;
- Undergoing a clinically indicated cardiac surgical procedure: CABG, AVR, ascending aorta replacement, or combinations thereof;
- Documented history of paroxysmal or persistent AF
- Provide informed consent
Exclusion Criteria:
-
Dominant atrial arrhythmia is atrial flutter;
-
Documented left atrial diameter ≥ 6 cm;
-
Previous cardiac surgery requiring opening of the pericardium;
-
Patients undergoing any of the following procedures:
- Heart transplant
- Complex congenital heart surgery
- Sole indication for surgery is ventricular assist device insertion
- Mitral valve repair or replacement
- Tricuspid valve repair or replacement
-
Patient resides in a long-term care facility
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Surgical Atrial Fibrillation Ablation Group
Surgeon will perform left atrial ablation during patient's cardiac surgery procedure. |
Surgeon will preform surgical atrial fibrillation ablation using either cryoablation or bipolar radiofrequency clamps including 2 layers of atrium or vein, a minimum of 2 burns per clamping with at least 3 lines in the ablation group. Cavo-tricuspid isthmus and mitral lines will be allowed. |
|
Aucune intervention: No Surgical Atrial Fibrillation Ablation Group
Surgeon will not perform left atrial ablation during the patient's cardiac surgery procedure. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of hospital readmissions for heart failure over duration of follow-up
Délai: Common termination point for trial (median follow-up of 4 years)
|
Total number of hospital readmissions for heart failure. |
Common termination point for trial (median follow-up of 4 years)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Ischemic stroke or systemic arterial embolism events over duration of follow up
Délai: Common termination point for trial (median follow-up of 4 years)
|
Number of Ischemic stroke or systemic arterial embolism events over duration of follow up |
Common termination point for trial (median follow-up of 4 years)
|
|
Length of ICU stay
Délai: From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
|
Length of ICU stay, including readmissions, from study intervention surgery to hospital discharge, including readmissions |
From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
|
|
Length of hospital stay
Délai: From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
|
Length of hospital stay |
From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
|
|
Freedom from recurrence of atrial tachyarrhythmia
Délai: 1 year post-operatively
|
Freedom from recurrence of atrial tachyarrhythmia |
1 year post-operatively
|
|
Number of days free from admission to healthcare facility or presentation to the emergency department for heart failure
Délai: Common termination point for trial (median follow-up of 4 years)
|
Number of days free admission to healthcare facility or presentation to the emergency department for heart failure |
Common termination point for trial (median follow-up of 4 years)
|
|
All-cause mortality
Délai: Common termination point for trial (median follow-up of 4 years)
|
All-cause mortality |
Common termination point for trial (median follow-up of 4 years)
|
|
Cardiovascular mortality
Délai: Common termination point for trial (median follow-up of 4 years)
|
Cardiovascular mortality |
Common termination point for trial (median follow-up of 4 years)
|
|
Antiarrhythmic drug use
Délai: Beyond 6 weeks until common termination point for trial (median follow-up of 4 years)
|
Antiarrhythmic drug use |
Beyond 6 weeks until common termination point for trial (median follow-up of 4 years)
|
|
Number of patients undergoing atrial fibrillation ablation
Délai: 90 days post- study surgery until common termination point for trial (median follow-up of 4 years)
|
Number of patients undergoing atrial fibrillation ablation |
90 days post- study surgery until common termination point for trial (median follow-up of 4 years)
|
|
Quality of Life - atrial fibrillation specific
Délai: At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
Atrial fibrillation specific quality of life as assessed by the Atrial Fibrillation Effect on QualiTy of Life questionnaire (AFEQT) which is 20 questions using a 7 point Likert scale where a higher score means a worse outcome. |
At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
|
Quality of Life - heart failure specific
Délai: At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
Heart failure specific quality of life assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) which is a 12 questions using Likert scales where a higher score is a better outcome. |
At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
|
Quality of Life - General
Délai: At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
Quality of life- general as assessed by the European quality of life index version 5D (EQ-5D-5L) which consists of a descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement. |
At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Ischemic stroke and systemic arterial embolism
Délai: Up to 30 days post-operatively
|
Safety outcome |
Up to 30 days post-operatively
|
|
Number of patients requiring permanent pacemaker implantation
Délai: Up to 1 year post-operatively
|
Safety outcome |
Up to 1 year post-operatively
|
|
Volume of chest tube output
Délai: Up to 24 hours post-operatively
|
Safety outcome - chest tube output measured in mL. |
Up to 24 hours post-operatively
|
|
Re-operation for bleeding
Délai: From date of study intervention surgery completion to date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
|
Safety outcome |
From date of study intervention surgery completion to date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
|
|
All-cause mortality
Délai: Prior to discharge or within 30 days post-operatively (whichever occurs first)
|
Safety outcome |
Prior to discharge or within 30 days post-operatively (whichever occurs first)
|
|
Post-operative major bleeding
Délai: <48 hours after surgery
|
Safety outcome |
<48 hours after surgery
|
|
Number of patients with pulmonary vein stenosis
Délai: At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
Safety outcome |
At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
|
Number of patients with stiff left atrium syndrome
Délai: At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
Safety outcome |
At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
|
Number of patients with esophageal to atrial fistula
Délai: At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
Safety outcome |
At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
|
Health economic analysis of surgical atrial fibrillation
Délai: At 1 year, and at common termination point (median follow-up of 4 years)
|
Economic analysis will be assessed via health care utilization by patients |
At 1 year, and at common termination point (median follow-up of 4 years)
|
|
Health economic analysis of surgical atrial fibrillation
Délai: At 1 year, and at common termination point (median follow-up of 4 years)
|
Economic analysis will be assessed via a questionnaire of health care visits and costs incurred by patients. |
At 1 year, and at common termination point (median follow-up of 4 years)
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Richard Whitlock, Population Health Research Institute
- Chercheur principal: Emilie Belley-Côté, Population Health Research Institute
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SAFEV1.0
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .